Edward Currie

MBBS, MSc, DipPharmMed
Head of CNS & Pain
Edward Currie

Ed focus is on CNS, as well as oncology and infectious disease, both in the areas of clinical development and medical affairs. He also brings experience in ophthalmology, tissue repair, personalised medicine, diagnostics, and digital health. 
A medical doctor by training, Ed has 30 years of industry experience in the UK, Germany and Switzerland. He qualified in medicine in the UK and worked for 7 years in London teaching hospitals, with specialist training in infection. He entered the pharmaceutical industry with Eli Lilly, managing the international multi-indication clinical development programmes from first patient through regulatory filings into Phase IV. 
He then moved to Basel (where he remains based), to join F. Hoffmann-La Roche as Medical Director of their global oncology/virology business unit. Subsequent roles at Roche were in oncology as Global Business Leader for MabThera (rituximab), in ophthalmology as Global Business Leader, and in diagnostics/personalised medicine as Founder/Head of Disease Management and Program Manager for Integrated Health Care Solutions.
Ed subsequently had leadership positions in venture-backed medical device companies, as COO of Swiss biotech/medtech Kuros Biosurgery, and as Head of Corporate Development at German diagnostics company SIRS-Lab. He has also held pharmaceutical consulting and business development roles at IBM and Infosys/Lodestone, has been an advisor to several start-up companies, and is on the Advisory Board of FutureHealth Basel.
Since joining tranScrip in May 2017, Ed has worked on multiple client projects in neuroscience, oncology, infectious diseases, immunology, dermatology and diagnostics.